Valuation: Adial Pharmaceuticals, Inc.

Market Cap 11.42M 10.19M 9.49M 8.64M 16.27M 1.1B 16.39M 115M 44.63M 561M 42.88M 41.96M 1.8B P/E 2026 *
-2.88x
P/E 2027 * -7.13x
Enterprise Value 11.42M 10.19M 9.49M 8.64M 16.27M 1.1B 16.39M 115M 44.63M 561M 42.88M 41.96M 1.8B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.92%
Yield 2026 *
-
Yield 2027 * -
1 day+5.58%
1 week+7.67%
Current month+8.48%
1 month-38.90%
3 months+50.00%
6 months+157.40%
Current year-20.91%
1 week 3.86
Extreme 3.86
4.66
1 month 3.77
Extreme 3.77
7.2
Current year 1.31
Extreme 1.31
7.2
1 year 1.31
Extreme 1.31
10.75
3 years 1.31
Extreme 1.31
104.25
5 years 1.31
Extreme 1.31
2,906.25
10 years 1.31
Extreme 1.31
5,900
Manager TitleAgeSince
Chief Executive Officer 65 17/08/2022
Director of Finance/CFO 63 15/11/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 76 31/01/2015
Director/Board Member 46 31/08/2014
Chairman 57 17/08/2022
Date Insider Type Main position Quantity % Market Cap. Importance
17/09/26 Free

Director

25,666 0.9774%
07/04/26 Free

Chief Financial Officer

17,325 1.2133%
07/04/26 Free

Chairman

9,185 0.6432%
Change 5-day change 1-year change 3-year change Capi.($)
+5.58%+7.67%-56.33%-93.72% 11.42M
+4.16%+3.42%+49.37%+94.17% 74.31B
+1.62%-2.69%+21.45%+76.56% 56.95B
+2.05%+0.75%+5.60%+37.16% 48.3B
+0.50%+2.94%+344.62%+722.17% 44.51B
+3.05%-1.80%+28.78%+34.51% 43.8B
+1.00%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.42%+8.04%+37.62%+32.27% 28.97B
+0.76%-1.45%-7.44%-11.12% 24.53B
Average +2.25%+0.63%+43.81%+106.28% 39.36B
Weighted average by Cap. +2.10%-0.46%+58.87%+136.95%

Financials

2026 *2027 *
Net sales - -
Net income -65.46M -58.4M -54.41M -49.51M -93.24M -6.3B -93.93M -657M -256M -3.22B -246M -240M -10.34B -21.14M -18.86M -17.57M -15.99M -30.11M -2.04B -30.33M -212M -82.59M -1.04B -79.35M -77.64M -3.34B
Net Debt - -
Logo Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.
Employees
5
Date Price Change Volume
05/10/26 US$4.350 +5.58% 60,025
02/10/26 US$4.120 -0.24% 64,504
01/10/26 US$4.130 +2.99% 13,388
30/09/26 US$4.010 -3.37% 35,322
29/09/26 US$4.150 +2.72% 29,320
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.350USD
Average target price
8.333USD
Spread / Average Target
+91.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADIL Stock